SANA Key Statistics, Chart & Performance
The current stock price of SANA is 5.13 USD. In the past month the price increased by 26.67%. In the past year, price increased by 123.04%.
SANA Latest News, Press Relases and Analysis
SANA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About SANA
Company Profile
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Company Info
SANA BIOTECHNOLOGY INC
188 East Blaine Street, Suite 400
Seattle WASHINGTON 98102 US
CEO: Steven D. Harr
Employees: 194
Phone: 12067017914
SANA BIOTECHNOLOGY INC / SANA FAQ
Can you describe the business of SANA BIOTECHNOLOGY INC?
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 194 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
What is the stock price of SANA BIOTECHNOLOGY INC today?
The current stock price of SANA is 5.13 USD. The price decreased by -0.97% in the last trading session.
What is the dividend status of SANA BIOTECHNOLOGY INC?
SANA does not pay a dividend.
How is the ChartMill rating for SANA BIOTECHNOLOGY INC?
SANA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does SANA BIOTECHNOLOGY INC have?
SANA BIOTECHNOLOGY INC (SANA) currently has 194 employees.
What is the outstanding short interest for SANA BIOTECHNOLOGY INC?
The outstanding short interest for SANA BIOTECHNOLOGY INC (SANA) is 13.36% of its float.
SANA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is one of the better performing stocks in the market, outperforming 96.9% of all stocks.
SANA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SANA. The financial health of SANA is average, but there are quite some concerns on its profitability.
SANA Financial Highlights
Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 41.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.83% | ||
| ROE | -120.02% | ||
| Debt/Equity | 0 |
SANA Forecast & Estimates
15 analysts have analysed SANA and the average price target is 8.74 USD. This implies a price increase of 70.43% is expected in the next year compared to the current price of 5.13.